

Special Issue

Innovative Drug Treatment of Cancer Cells

Message from the Guest Editors

Tumor removal by surgery is the most important step in the management of patients with cancers. Many patients present a high risk of relapse and metastasis even when the primary tumor is diagnosed and surgically excised at an early stage. Chemotherapy is often used to improve the recurrence-free survival of patients. Patients with blood cancer are also often treated with chemotherapy, which sometimes consists of the use of several drugs together in a set regimen. However, a minority of patients experience a sustained benefit of this treatment, which unfortunately presents side effects so severe that it often makes the patients unable to attain target drug doses shown to give a survival benefit. The Special Issue on the "Innovative Drug Treatment of Cancer Cells" will focus on new therapeutic options to improve cancer treatment outcomes and increase the overall survival of patients. We encourage the submission of manuscripts (original research and reviews) including new drugs targeting already-known targets of cancer cells, drugs targeting new specific targets of cancer cells or cancer stem cells, and new combinations of targeted or classical chemotherapies.

Guest Editors

Dr. Isabelle Mus-Veteau

Institute of Molecular and Cellular Pharmacology (IPMC), French National Centre for Scientific Research (CNRS), 06560 Valbonne, France

Dr. Frédéric Luton

Institute of Molecular and Cellular Pharmacology (IPMC), French National Centre for Scientific Research (CNRS), 06560 Valbonne, France

Deadline for manuscript submissions

closed (20 October 2022)



Cells

an Open Access Journal
by MDPI

Impact Factor 5.1
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/105945

Cells
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.1
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Prof. Dr. Alexander E. Kalyuzhny

Neuroscience, UMN Twin Cities, 6-145 Jackson Hall, 321 Church St SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2024).